10-K: HCW Biologics Faces Going Concern Doubt Amid Losses

HCW Biologics Inc. reported significant losses and a material weakness in internal controls, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

Summary

• HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases linked to chronic inflammation, including autoimmune disorders, cancer, and senescence-associated dysplasia.
• The company reported a net loss of $7.96 million for the year ended December 31, 2025, an improvement from a $30.02 million net loss in 2024.
• Cumulative net losses since inception reached $105.8 million as of December 31, 2025.
• Cash and cash equivalents stood at $2.0 million as of December 31, 2025, leading to substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• A material weakness in internal control over financial reporting was identified related to the assessment of long-lived assets for impairment, resulting in a $1.5 million impairment charge on the company's building.
• The company initiated a Phase 1 clinical trial for HCW9302 in patients with alopecia areata on November 17, 2025, with two active clinical sites and no dose-limiting toxicities reported as of March 16, 2026.
• Preclinical molecules HCW11-018b (tetra-valent T-Cell engager for solid tumors) and HCW11-040 (second-generation immune checkpoint inhibitor for BPD) are expected to have IND applications submitted in the first and second half of 2027, respectively.
• HCW9206 and HCW9201 are commercial-ready proprietary compounds for use as reagents in the production of CAR-T and NK cell-based immunotherapies, respectively.
• A publication in Science Advances on March 13, 2026, highlighted HCW9206's potential to improve CAR-T cell therapy manufacturing and performance against cancer and HIV.
• The company secured a licensing agreement with Beijing Trimmune Biotech Co., Ltd. for HCW11-006, receiving a $3.5 million upfront cash payment (net $2.9 million after taxes) and a minority equity interest in Trimmune, with Trimmune funding Phase 1 trials in China expected mid-2027.
• HCW Biologics retains an Opt-In Right for the Americas market for HCW11-006 and an option for Trimmune to license China rights for HCW9302.
• Legal fees related to a past arbitration with Altor/NantCell and ImmunityBio, totaling $7.5 million, were settled for $2.0 million in cash payments and a $5.5 million contingent promissory note deemed remote as of December 31, 2025.
• The company raised $11.5 million in gross proceeds from financing activities in 2025, including $2.5 million from a Standby Equity Purchase Agreement (SEPA) and $4.0 million from a warrant inducement transaction.
• A follow-on public offering in February 2026 raised approximately $1.5 million in gross proceeds.
• The company regained compliance with Nasdaq's continued listing rules as of February 26, 2026, but received a new notice on March 26, 2026, for not maintaining a minimum bid price of $1 per share.
• The company is building a 36,000 sq ft headquarters in Miramar, Florida, for manufacturing and R&D, but completion is uncertain, and legal proceedings related to mechanics liens and unpaid construction invoices are ongoing.
• The company settled with B&I Contractors for $860,000 in installments, with the last payment due by May 31, 2026.
• Cogent Bank issued a demand on October 24, 2025, for the company to cure mechanics liens on its property within 30 days, with negotiations for a forbearance agreement ongoing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant going concern doubts, recurring losses, a material weakness in internal controls, and ongoing legal and Nasdaq compliance challenges, despite some positive clinical and financing developments.

Positives

• Net loss significantly decreased to $7.96 million in 2025 from $30.02 million in 2024.
• Initiated a Phase 1 clinical trial for HCW9302 in alopecia areata, a major milestone in autoimmune disease development, with no dose-limiting toxicities reported.
• Proprietary compound HCW9206 was highlighted in Science Advances for its potential to revolutionize CAR-T cell therapy manufacturing and efficacy against cancer and HIV.
• Secured a licensing agreement with Beijing Trimmune Biotech Co., Ltd. for HCW11-006, including a $3.5 million upfront cash payment and a minority equity interest, with Trimmune funding Phase 1 trials in China.
• Successfully raised $11.5 million in gross proceeds from financing activities in 2025 and an additional $1.5 million in February 2026.
• Settled $7.5 million in outstanding legal fees for $2.0 million cash and a contingent promissory note, reducing immediate financial burden.
• Regained compliance with Nasdaq's continued listing rules as of February 26, 2026, demonstrating efforts to maintain public market access.
• The company retains significant intellectual property rights, including worldwide exclusive license for HCW9206 and HCW9302 for all indications, and HCW9218 for non-oncology age-related diseases.
• Dr. Hing C. Wong, Founder and CEO, has a strong track record, including the development of Anktiva, a blockbuster immunotherapeutic acquired for $1.0 billion and FDA-approved in 2024.

Negatives

• Reported a net loss of $7.96 million in 2025 and cumulative net losses of $105.8 million since inception.
• Cash and cash equivalents of $2.0 million as of December 31, 2025, raise substantial doubt about the company's ability to continue as a going concern.
• Identified a material weakness in internal control over financial reporting related to impairment assessment of long-lived assets, leading to a $1.5 million impairment charge on its building.
• Received a new Nasdaq notice on March 26, 2026, for failing to maintain a minimum bid price of $1 per share, risking delisting.
• Ongoing legal proceedings and mechanics liens totaling $6.2 million related to unpaid construction invoices for the new headquarters, with a demand from Cogent Bank to cure these defaults.
• Revenue from the Wugen License decreased significantly from $2.6 million in 2024 to $54,232 in 2025 due to Wugen's strategic shift and suspension of the license.
• The company incurred a $1.3 million nonoperating loss in 2024 due to a fraudulent criminal scheme involving misdirected funds.
• The company's stock price has been highly volatile and subject to significant fluctuations.
• Existing stockholders will suffer significant dilution if Proposal One and Two are approved due to the issuance and repricing of warrants.

Risks

• Significant financial losses and expected future losses, with no products approved for commercial sale, may prevent the company from achieving or maintaining profitability.
• Substantial doubt about the ability to continue as a going concern due to insufficient cash and cash equivalents, requiring additional funding that may not be available on acceptable terms or at all.
• Failure to maintain an effective system of internal control over financial reporting could impair the ability to produce timely and accurate financial statements and lead to a decline in stock price.
• Outstanding legal fee obligations and construction-related liabilities could have a material negative impact on business and operations.
• Risk of delisting from Nasdaq due to failure to maintain minimum bid price or other listing standards, which would negatively affect stock price and liquidity.
• Clinical trials may fail to demonstrate safety and efficacy, preventing or delaying regulatory approval and commercialization.
• Preliminary or interim clinical data may change, leading to material changes in final data and potential volatility in stock price.
• The regulatory approval process for biopharmaceutical products is lengthy, expensive, and unpredictable, with no guarantee of timely approval.
• Prolonged or delayed clinical trials could prevent timely regulatory approvals and commercialization, increasing costs and slowing development.
• Ongoing regulatory obligations and review post-approval may result in significant additional expense, labeling restrictions, or market withdrawal.
• Reliance on patents and other intellectual property rights for protection, which may be challenging, time-consuming, and costly to prosecute, enforce, defend, and maintain.
• Dependence on third parties for manufacturing product candidates, with risks of failure to produce acceptable drug substance, regulatory non-compliance, supply chain disruptions, and increased costs.
• Information technology systems, or those of third-party contractors, may fail or suffer security breaches, leading to loss of intellectual property, data compromise, regulatory actions, and reputational harm.
• Unfavorable global economic conditions, including inflation, rising interest rates, and geopolitical tensions, could adversely affect business, financial condition, and stock price.
• Inability to successfully identify, develop, and commercialize additional product candidates could impair growth.
• Even if approved, products may not gain market acceptance, failing to generate significant product revenues.
• Lack of internal marketing, sales, or distribution infrastructure, with risks associated with establishing or outsourcing these functions.
• Failure to realize benefits from co-development or out-licensing arrangements, or inability to enter new strategic relationships, could adversely affect business and financial condition.
• Potential exposure to costly and damaging product liability claims, with insurance coverage possibly being inadequate.
• Uncertainty regarding new administration's initiatives and their impact on FDA regulations, funding, and personnel, potentially delaying development and approval.
• Compliance with various healthcare laws and regulations (anti-kickback, false claims, privacy) is costly and complex, with potential for significant penalties for non-compliance.
• Risks associated with the use of new and evolving technologies like artificial intelligence, including data security, privacy, regulatory compliance, and intellectual property risks.
• The company's future growth and ability to compete depend on retaining key personnel and recruiting additional qualified personnel, which is challenging in a competitive industry.

Future Outlook

HCW Biologics plans to continue advancing its lead product candidates, HCW9302, HCW11-018b, and HCW11-040, through clinical development, with IND applications for preclinical programs expected in 2027. The company intends to explore additional indications for HCW9302 in Phase 2 studies, focusing on autoimmune and inflammatory conditions. Business development transactions, including out-licensing, are a key component of the financing strategy to fund operations and clinical development. The company is actively seeking alternate licensees for its commercial-ready reagents HCW9206 and HCW9201. Efforts are ongoing to complete the new headquarters and manufacturing facility, and the company expects to pursue other capital-raising transactions in 2026, with an emphasis on strategic investors and business development. The company will also continue to monitor and address Nasdaq listing compliance.

Management Comments

• "We want our products to improve patients healthspan as well as their quality of life, and possibly extend longevity."
• "With the start of the first-in-human clinical trial for HCW9302 in alopecia areata, we are one step closer to advancing a potentially transformative immunotherapeutic treatment of autoimmune diseases. This trial is a milestone for our Company, and the beginning of clinical development of treatments for quality-of-life indications."
• "While not life-threatening, alopecia areata has no cure and diminishes the quality of life for those suffering with this disease. Existing treatments may provide some relief of symptoms, but there are often serious side effects."
• "If this Phase 1 study is successful, we intend to rapidly advance clinical development of HCW9302 in Phase 2 studies in patients with other autoimmune diseases and serious inflammatory conditions, including graft rejection, neurodegenerative diseases, and other dermatological conditions, such as atopic dermatitis and vitiligo."
• "The Company remains committed to establishing some control over our clinical supply of materials, and the supply of licensed molecules for our licensees, as well as other clinical-stage companies developing biologics."
• "Management concluded that there were no mitigating circumstances which alleviated the substantial doubt over its ability to continue as a going concern. If the Company is not successful in raising additional capital through these activities, management intends to revise its business plan and reduce costs. If such revisions are insufficient, the Company may have to curtail or cease operations."

Industry Context

StockSavvy.ai notes that HCW Biologics operates in the highly competitive and rapidly evolving biopharmaceutical industry, particularly focusing on chronic inflammation, autoimmune diseases, cancer, and senescence-associated dysplasia. The company's strategy to target diseases with no known FDA-approved treatments, such as alopecia areata, aligns with a growing industry trend to address unmet medical needs. The development of novel fusion immunotherapeutics, like HCW9302 and the 'Big BiTE' HCW11-018b, positions HCW Biologics against major pharmaceutical and biotechnology companies like Amgen, Merck & Co., and Bristol Myers Squibb, which are also active in IL-2 modulation and T-cell engagers. The commercialization of reagents like HCW9206 for CAR-T manufacturing taps into the expanding cell therapy market, where efficiency and cost-effectiveness are critical. The increasing focus on aging-related diseases and senescence removal by innovators like Altos Labs and Pfizer indicates a significant market opportunity that HCW Biologics is also pursuing. However, the industry is characterized by high R&D costs, lengthy regulatory processes, and intense competition, which HCW Biologics must navigate with its limited resources.

Comparison to Industry Standards

• HCW Biologics' HCW9302 is a first-in-kind IL-2 fusion protein, aiming to overcome limitations of recombinant IL-2 (e.g., unfavorable pharmacokinetics, cytokine release syndrome) which is a common challenge for IL-2 based therapies from competitors like Amgen and Nektar Therapeutics.
• The 'Big BiTE' (HCW11-018b) is designed to address key challenges of first-generation T-Cell Engagers, such as manufacturability, preclinical safety, and solid tumor treatment, differentiating it from conventional BiTEs and multispecific platforms from companies like Amgen, Genmab/Daiichi Sankyo.
• HCW11-040 aims to expand Tpex cells without cytokine storm, a common issue with immune checkpoint inhibitors like Keytruda (pembrolizumab) from Merck & Co., suggesting a potentially superior safety profile.
• The $1.0 billion acquisition of Anktiva (ALT-803), an IL-15 agonist receptor discovered by HCW Biologics' CEO, by ImmunityBio in 2017 and its subsequent FDA approval in 2024, demonstrates a track record of developing high-value immunotherapeutics, a benchmark for success in the biotech industry.
• The company's revenue from the Wugen License decreased significantly from $2.6 million in 2024 to $54,232 in 2025, which is a substantial drop compared to typical revenue growth expectations for companies with active licensing agreements, especially given Wugen's Breakthrough Therapy Designation for Sofi-cel.
• The reported net loss of $7.96 million in 2025, while an improvement from $30.02 million in 2024, still reflects significant cash burn typical of clinical-stage biopharma but raises going concern doubts, which is a critical concern for investors compared to more financially stable industry peers.
• The $1.5 million impairment on the building and ongoing legal disputes related to construction liens indicate operational and financial challenges that are not standard for well-managed companies in the industry, potentially impacting capital allocation for core R&D.

Corporate Governance

Legal Proceedings

• Arbitration with Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc. against the Company and Dr. Hing C. Wong was settled on July 13, 2024, and dismissed with prejudice on December 24, 2024. No monetary payments were required between parties, but the Company assigned certain intellectual property to ImmunityBio while retaining rights to key molecules.
• A settlement agreement was reached with Cooley LLP on December 30, 2025 (amended March 23, 2026) for approximately $7.5 million in outstanding legal fees, settling for $2.0 million in cash payments ($500,000 paid Dec 31, 2025; $750,000 paid Mar 20, 2026; remaining $750,000 due by Aug 31, 2026 or earlier upon $4.0 million financing) and a $5.5 million contingent promissory note deemed remote.
• Legal proceedings initiated by BE&K Building Group (April 17, 2025) and Fisk Electric Company (April 28, 2025) in Florida Circuit Court regarding mechanics liens and unpaid construction invoices for the new headquarters. These cases have been consolidated, and a trial is set for early December 2026.
• A settlement and release agreement was submitted to the Court on February 19, 2026, between the Company and B&I Contractors, Inc. for $860,000 in installments, with the last payment due by May 31, 2026.
• Cogent Bank issued a demand on October 24, 2025, requiring the Company to cure mechanics liens on its mortgaged property within 30 days, with negotiations for a forbearance agreement ongoing.

Related Party Transactions

• Dr. Hing C. Wong (Founder and CEO), Rebecca Byam (CFO), Lee Flowers (SVP Business Development), Scott T. Garrett (Chairman), and Gary M. Winer (Director) invested $2.9 million in Secured Notes out of a total of $6.9 million issued by the company as of October 31, 2024.
• In May 2025, $6.6 million of Secured Notes held by certain noteholders (including related parties) were restructured and converted to equity, resulting in a $3.5 million troubled debt restructuring gain recorded to additional paid-in capital due to the related party nature.
• Dr. Hing C. Wong ($60,000), Scott T. Garrett ($100,000), and Gary M. Winer ($10,000) invested in $270,000 of unsecured convertible promissory notes, which were converted to equity in May 2025, resulting in a $131,135 loss on conversion recorded to additional paid-in capital due to the related party nature.
• On May 8, 2025, the company issued a $150,000 promissory note with a personal guarantee from Dr. Hing C. Wong, which was repaid in full on February 6, 2026.
• Financing transactions in May 2025 and November 2025 with a single institutional investor (Armistice Capital Master Fund Ltd.), an existing stockholder, resulted in a total deemed equity dividend to the investor of $14.3 million, recorded in additional paid-in capital.
• The settlement agreement with Cooley LLP regarding Dr. Wong's legal fees involved a $7.5 million obligation settled for $2.0 million cash and a $5.5 million contingent promissory note.

Stakeholder Impact

• **Shareholders:** Face significant dilution from recent and proposed warrant issuances and repricing. The substantial doubt about going concern and Nasdaq delisting risk could severely impact share price and liquidity. However, successful clinical trial progression and capital raises offer potential for future value creation.
• **Employees:** The company's ability to attract, retain, and motivate highly-skilled scientific, technical, and managerial employees is crucial for future success, especially given the competitive industry. Staff reductions in May 2024 indicate past challenges, but ongoing efforts to build out facilities and advance programs could provide stability.
• **Customers/Licensees:** Wugen's suspension of its license and strategic shift impacts a key revenue stream. The Trimmune partnership offers new development and commercialization opportunities. Commercial-ready reagents HCW9206 and HCW9201 aim to serve the broader immunotherapeutics production market.
• **Creditors:** Cogent Bank and construction subcontractors are impacted by outstanding liabilities and mechanics liens, leading to legal proceedings and demands for cure. The settlement agreements with Cooley LLP and EirGenix address some past due amounts but highlight ongoing financial pressures.
• **Regulatory Bodies:** The company's compliance with FDA and Nasdaq regulations is under scrutiny, with recent notices of non-compliance and a mandatory panel monitor. Failure to meet these standards could hinder product approvals and market access.

Next Steps

• Continue enrollment and treatment of subjects in the Phase 1 dose-escalation clinical trial for HCW9302 in alopecia areata.
• Establish Recommended Phase 2 Dose (RP2D) and safety for HCW9302 in the Phase 1 study.
• Evaluate other carefully selected indications for HCW9302 in Phase 2, including other autoimmune diseases, inflammatory conditions, graft rejection, and neurodegenerative diseases.
• Complete IND-enabling studies and submit an IND application for HCW11-018b (tetra-valent T-cell engager for solid tumors) in the first half of 2027.
• Complete IND-enabling studies and submit an IND application for HCW11-040 (second-generation immune checkpoint inhibitor for BPD) in the second half of 2027.
• Continue to build relationships with leading clinical research centers to reduce patient recruitment risks.
• Assess optimal approaches for clinical development or commercialization with each milestone for lead product candidates.
• Actively search for corporate partners for commercial-ready reagents HCW9206 and HCW9201.
• Monitor results of IND-enabling studies and Phase 1 clinical study for HCW11-006 by Trimmune before deciding on the Opt-In Right for the Americas market.
• Implement remediation plans to strengthen internal controls over financial reporting, including obtaining annual appraisals and monitoring impairment indicators.
• Pursue financing alternatives to come current on past due amounts and complete the construction and renovation of the Miramar property.
• Negotiate a forbearance agreement with Cogent Bank regarding the demand to cure mechanics liens.
• Continue discovery in the consolidated BE&K and Fisk complaints, with a trial set for early December 2026.
• Hold a Special Stockholders Meeting on April 27, 2026, to vote on proposals regarding warrant issuance and repricing.
• Pay the remaining $750,000 to Cooley LLP by August 31, 2026, or earlier upon completion of a $4.0 million financing.
• Pay the remaining $620,000 to EirGenix by April 30, 2026, to avoid increased payment obligations.
• Appeal Nasdaq's determination regarding non-compliance with the minimum bid price rule.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial doubt about its ability to continue as a going concern, recurring net losses, and critically low cash reserves. The material weakness in internal controls and ongoing legal battles over unpaid construction bills further highlight operational and financial instability. While there are promising clinical developments and recent capital raises, these are insufficient to offset the immediate and significant risks. The recent Nasdaq non-compliance notice for minimum bid price, following a reverse stock split, indicates persistent market challenges and a high probability of further share price volatility and potential delisting. The significant dilution from recent and proposed warrant transactions also negatively impacts existing shareholder value. Given these compounding factors, a seasoned investor would likely recommend selling to mitigate further risk.

Keywords

Immunotherapeutics, Biopharmaceutical, Clinical-stage, Chronic inflammation, Autoimmune diseases, Cancer, Senescence-associated dysplasia, HCW9302, Alopecia areata, CAR-T cell therapy, NK cell therapy, HCW9206, HCW9201, Nasdaq compliance, Capital raise, SEC filing, Biotech, Drug development, Clinical trials, Intellectual property